Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours Β· Estimated delivery Aug 17 - Aug 22
By activating receptors for GLP-1, GIP, and glucagon, it sends powerful signals to your brain and body to reduce hunger, stabilize blood sugar, and increase energy expenditure
After 18 months on GLP-1 receptor agonists, the proportion of men with healthy testosterone rose to 77%
Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
Increased sympathetic nervous system activity GLP-1 receptor agonists like Wegovy may stimulate the sympathetic nervous systemthe part of your body responsible for the "fight or flight" response
US$ 23.88
US$ 24.35
US$ 24.59
US$ 25.13
US$ 28.57
